Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Tempus AI Inc TEM
$82.58
βΌ -2.94%
($-2.50)
⬇️ Below Yest. Low
🎢 High Beta
Open
$85.49
Prev Close
$85.08
Day Range
$81.78 β $89.09
52W Range
$40.77 β $104.32
Market Cap
$14.90B
Beta
2.29
EPS (TTM)
$-1.43
π Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-05-30 |
| Shares Out. | 180,240,000 |
| Website | investors.tempus.com/ β |
| Phone | 18335144187 |
| Employees | 3,800 |
| Revenue | $382.5M |
| Gross Profit | $246.5M |
| Net Income | $5.6M |
| Free Cash Flow | -$263.2M |
| Total Assets | $2.37B |
| Total Liabilities | $1.92B |
| Equity | $444.9M |
About Tempus AI Inc
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Tempus AI Inc is a publicly traded company under the ticker symbol TEM on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
23 analysts (2026-09-01)
π° Latest News for TEM
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI Receives 510(k) Clearance From FDA For Tempus ECG-MR, AI Product That Analyzes Standard 12-Lead Resting Ecgs To Detect Signs Associated With Undiagnosed Mitral Regurgitation
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
10 Health Care Stocks Whale Activity In Todayβs Session
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
Tempus AI: High Risk, But With A Great Cause

